Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 in Recurrent or Extensive-Stage Small Cell Lung Cancer
NCT00003496Phase 2Terminated
- Sponsor
- Burzynski Research Institute
- Start
- Mar 1996
- Primary completion
- Feb 2004
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in small cell lung cancer (SCLC), sponsored by Burzynski Research Institute. Started Mar 1996; status: terminated.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00003496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003496.